Examkin

Question

Difficulty: Very hardInfectious Diseases

Match each clinical presentation of a newly diagnosed HIV patient with the most appropriate timing and rationale for initiating antiretroviral therapy (ART).

  • A 3535-year-old patient with newly diagnosed HIV (CD4 count 3030 cells/mm3\text{mm}^3) presents with progressive headache, fever, and lethargy. Cerebrospinal fluid analysis reveals a significantly elevated opening pressure and a positive polysaccharide antigen test.Defer initiation of antiretroviral therapy (ART) for at least 22 to 1010 weeks after commencing targeted induction therapy to minimize the risk of severe central nervous system inflammation.
  • A 4242-year-old patient with newly diagnosed HIV (CD4 count 4545 cells/mm3\text{mm}^3) presents with chronic cough, night sweats, and weight loss. Sputum smear is positive for acid-fast bacilli.Initiate antiretroviral therapy (ART) within 22 weeks of commencing targeted antimicrobial therapy to maximize survival benefit.
  • A 2929-year-old patient with newly diagnosed HIV (CD4 count 160160 cells/mm3\text{mm}^3) presents with a cavitary apical lung lesion. Sputum nucleic acid amplification testing is positive for Mycobacterium tuberculosis.Initiate antiretroviral therapy (ART) between 22 and 88 weeks after commencing targeted antimicrobial therapy, as earlier initiation offers no survival benefit and increases the risk of adverse events.
  • A 5050-year-old patient with newly diagnosed HIV (CD4 count 3535 cells/mm3\text{mm}^3) presents with unilateral blurred vision and floaters. Fundoscopic examination reveals perivascular yellow-white retinal exudates and prominent retinal hemorrhages.Defer initiation of antiretroviral therapy (ART) for 11 to 22 weeks after commencing targeted antiviral therapy to reduce the risk of localized, vision-threatening immune reconstitution.

Answer

The patient with cryptococcal meningitis matches with deferring ART 22 to 1010 weeks to prevent fatal CNS IRIS. The patient with tuberculosis and a CD4 count <50< 50 matches with initiating ART within 22 weeks to maximize survival. The patient with tuberculosis and a CD4 count >50> 50 matches with initiating ART between 22 and 88 weeks. The patient with CMV retinitis matches with deferring ART 11 to 22 weeks to prevent vision-threatening immune recovery uveitis.
The timing of ART initiation in the setting of acute opportunistic infections requires a delicate balance between rapidly restoring immune function to improve survival and avoiding Immune Reconstitution Inflammatory Syndrome (IRIS). For cryptococcal meningitis, the risk of fatal CNS IRIS is unacceptably high, necessitating a 22 to 1010 week delay. For tuberculosis, the survival benefit of very early ART (within 22 weeks) outweighs the risk of TB-IRIS only in profoundly immunosuppressed patients (CD4 <50< 50). For TB patients with CD4 counts >50> 50, ART should be delayed 22 to 88 weeks. For CMV retinitis, a 11 to 22 week delay is required to prevent immune recovery uveitis and subsequent blindness.

Step-by-Step Solution

1
Identify the underlying opportunistic infection (OI) for each patient based on the clinical presentation and diagnostic findings.
Patient 1 has cryptococcal meningitis, Patient 2 has active pulmonary tuberculosis, Patient 3 has active pulmonary tuberculosis, and Patient 4 has CMV retinitis.
Recognizing the specific OI is the critical first step because antiretroviral therapy (ART) initiation guidelines are inherently disease-specific.
2
Determine the patient's CD4 count for those with tuberculosis.
Patient 2 has a CD4 count <50< 50 cells/mm3\text{mm}^3, whereas Patient 3 has a CD4 count >50> 50 cells/mm3\text{mm}^3.
For active tuberculosis, the optimal timing of ART depends heavily on the degree of immunosuppression to balance the survival benefit against the risk of Immune Reconstitution Inflammatory Syndrome (IRIS).
3
Apply the guideline-based timing for ART initiation for each specific OI and CD4 category.
Cryptococcal meningitis requires a 22-1010 week delay; TB with CD4 <50< 50 requires ART within 22 weeks; TB with CD4 >50> 50 requires ART in 22-88 weeks; CMV retinitis requires a 11-22 week delay.
Following these specific guidelines minimizes the risk of fatal or organ-threatening IRIS while maximizing overall patient survival.

Key Concept

Timing of Antiretroviral Therapy (ART) Initiation in HIV-Associated Opportunistic Infections
Rate this question

Topics

Infectious Diseases

More questions from this topic